Home > Compound List > Product Information
CBIQ_Molecular_structure_CAS_32081-28-0)
Click picture or here to close

CBIQ

Catalog No. C6617 Name Sigma Aldrich
CAS Number 32081-28-0 Website http://www.sigmaaldrich.com
M. F. C13H8ClN Telephone 1-800-521-8956
M. W. 213.66232 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 154040

SYNONYMS

IUPAC name
4-chlorobenzo[f]isoquinoline
IUPAC Traditional name
4-chlorobenzo[f]isoquinoline
Synonyms
4-Chlorobenzo[f]isoquinoline

DATABASE IDS

PubChem SID 24724450
CAS Number 32081-28-0
MDL Number MFCD02179769

PROPERTIES

Empirical Formula (Hill Notation) C13H8NCl
Purity ≥98% (HPLC)
Apperance off-white solid
Solubility DMSO: soluble15 mg/mL
GHS Pictograms GHS05
GHS Pictograms GHS06
GHS Signal Word Danger
GHS Hazard statements H301-H315-H318-H335
European Hazard Symbols Toxic Toxic (T)
MSDS Link Download
Personal Protective Equipment Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
GHS Precautionary statements P261-P280-P301 + P310-P305 + P351 + P338
RID/ADR UN 2811 6.1/PG 3
Risk Statements 25-37/38-41
Safety Statements 26-39-45
Hazard Class 6.1
UN Number 2811
Packing Group 3
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
CBIQ is an activator of the cystic fibrosis transmembrane conductance regulator (CFTR) and the intermediate-conductance calcium-sensitive K+ channel (KCNN4). CBIQ is a novel tool for a new ion channel; first activator of ΔF508 CFTR, the mutant form of CFTR chloride channel present in 75% of cystic fibrosis patients. Other benzoquinolines act at the normal CFTR but not at ΔF508 CFTR. CBIQ also activates KCNN4, which hyperpolarizes airway epithelial cells to promote anion flux, a further benefit in cystic fibrosis.
Description (简体中文)
Biochem/physiol Actions
CBIQ is an activator of the cystic fibrosis transmembrane conductance regulator (CFTR) and the intermediate-conductance calcium-sensitive K+ channel (KCNN4). CBIQ is a novel tool for a new ion channel; first activator of ΔF508 CFTR, the mutant form of CFTR chloride channel present in 75% of cystic fibrosis patients. Other benzoquinolines act at the normal CFTR but not at ΔF508 CFTR. CBIQ also activates KCNN4, which hyperpolarizes airway epithelial cells to promote anion flux, a further benefit in cystic fibrosis.

REFERENCES